GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remed Co Ltd (XKRX:302550) » Definitions » Intrinsic Value: Projected FCF

Remed Co (XKRX:302550) Intrinsic Value: Projected FCF : ₩611.93 (As of Jun. 26, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Remed Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-26), Remed Co's Intrinsic Value: Projected FCF is ₩611.93. The stock price of Remed Co is ₩3580.00. Therefore, Remed Co's Price-to-Intrinsic-Value-Projected-FCF of today is 5.9.

The historical rank and industry rank for Remed Co's Intrinsic Value: Projected FCF or its related term are showing as below:

XKRX:302550' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 4.6   Med: 5.1   Max: 8.94
Current: 5.85

During the past 8 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Remed Co was 8.94. The lowest was 4.60. And the median was 5.10.

XKRX:302550's Price-to-Projected-FCF is ranked worse than
88.54% of 384 companies
in the Medical Devices & Instruments industry
Industry Median: 1.535 vs XKRX:302550: 5.85

Remed Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Remed Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remed Co Intrinsic Value: Projected FCF Chart

Remed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - 402.70

Remed Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 651.14 402.70 611.93

Competitive Comparison of Remed Co's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Remed Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remed Co's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remed Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Remed Co's Price-to-Projected-FCF falls into.


;
;

Remed Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Remed Co's Free Cash Flow(6 year avg) = ₩-1,454.16.

Remed Co's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar25)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-1454.15712+40740.424*0.8)/30.638
=611.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remed Co  (XKRX:302550) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Remed Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3580.00/611.92806781854
=5.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remed Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Remed Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Remed Co Business Description

Traded in Other Exchanges
N/A
Address
187 Techno 2-ro, No 301-303, Gwanpyeong-dong, Yuseong-gu, Daejeon, KOR, 34025
Remed Co Ltd is a Korean medical equipment manufacturing company. The company is engaged in researching and developing products to treat brain disorders such as depression, anxiety, stroke and Parkin's. It has developed TMS device and is manufacturing pain therapy devices using advanced electromagnetic stimulation, shockwave (RSWT) and laser technologies. Its products offerings include Transcranial Magnetic simulator for brain, Electromagnetic simulators including Salus Talent, Salus Talent A, Salus Talent Pro, and Optimus Pro for pain therapy; and Rosetta, Salus RSWT and Optimus Pro as a part of Extracorporeal Shockwave Therapy. It also offers Electrosurgical units from REMED including ELPIS 4L, ELPIS 4, ELPIS 3, and ELPIS2.

Remed Co Headlines

No Headlines